.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Cantor Fitzgerald
Mallinckrodt
Medtronic
Moodys
QuintilesIMS
Harvard Business School
US Army
Citi
Novartis

Generated: September 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Treatment of human viral infection
Abstract:Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
Inventor(s): Rideout; Janet L. (Raleigh, NC), Barry; David W. (Chapel Hill, NC), Lehrman; Sandra N. (Durham, NC), St. Clair; Martha H. (Durham, NC), Furman; Phillip A. (Durham, NC)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:07/111,208
Patent Claims: 1. A pharmaceutical preparation comprising a capsule containing 5 to 500 mg of 3'-azido-3'-deoxythymidine.

2. The capsule according to claim 1 containing 10 to 200 mg of 3'-azido-3'-deoxythymidine.

3. The capsule according to claim 1 containing 20 to 100 mg at 3'-azido-3'-deoxythymidine.

4. A tablet for oral administration containing 5 to 500 mg of 3'-azido-3'-deoxythymidine and a pharmaceutically acceptable solid carrier therefor.

5. A tablet according to claim 4 containing 10 to 200 mg of 3'-azido-3'-deoxythymidine.

6. A tablet according to claim 4 containing 20 to 100 mg of 3'-azido-3'-deoxythymidine.

7. A pharmaceutical preparation comprising a capsule containing 5 to 500 mg of a pharmaceutically acceptable salt of 3'-azido-3'-deoxythymidine.

8. A tablet for oral administration containing 5 to 500 mg of a pharmaceutically acceptable salt of 3'-azido-3'-deoxythymidine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Federal Trade Commission
Express Scripts
Medtronic
McKesson
Mallinckrodt
Farmers Insurance
Moodys
Healthtrust
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot